Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

Wallentin, Lars; C. Becker, Richard; Budaj, Andrzej; P. Cannon, Christopher; Emanuelsson, Håkan; Held, Claes; Horrow, Jay; Husted, Steen; James, Stefan; A. Katus, Hugo; W. Mahaffey, Kenneth; M. Scirica, Benjamin; M. Skene, Allan; Gabríel Steg, Philippe; F. Storey, Robert; A. Harrington, Robert

doi:10.1056/nejmoa0904327

Public

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

Published in New England Journal of Medicine • Aug 30, 2009

Authors:

Lars Wallentin

Richard C. Becker

Andrzej Budaj

Abstract

BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loadin...

Subject

Ticagrelor

Medicine

Clopidogrel

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!